News on Trubion Pharmaceuticals from BioPortfolio.com http://www.BioPortfolio.com Consolidated Trubion Pharmaceuticals news from BioPortfolio.com Wed, 10 Feb 2010 10:31:06 GMT en Trubion Pharmaceuticals Inc.-Therapeutic Competitors - new market report releasedhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4011234&HITNO=0&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4011234&THISHREF=http://c.moreover.com/click/here.pl%3fz2522828008%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4011234&HITNO=0&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4011234&THISHREF=http://c.moreover.com/click/here.pl%3fz2522828008%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR inside: Trubion Pharmaceuticals Inc.-Detailed Product Pipeline - new market report releasedhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3995242&HITNO=1&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3995242&THISHREF=http://c.moreover.com/click/here.pl%3fz2515549070%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3995242&HITNO=1&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3995242&THISHREF=http://c.moreover.com/click/here.pl%3fz2515549070%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR inside: Form 4 Trubion Pharmaceuticals, For: Jan 29 Filed by: BURRIS MICHELLEhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3994740&HITNO=2&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3994740&THISHREF=http://c.moreover.com/click/here.pl%3fz2515233669%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3994740&HITNO=2&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3994740&THISHREF=http://c.moreover.com/click/here.pl%3fz2515233669%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: Form 4 Trubion Pharmaceuticals, For: Jan 29 Filed by: Bencich Johnhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3994739&HITNO=3&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3994739&THISHREF=http://c.moreover.com/click/here.pl%3fz2515233649%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3994739&HITNO=3&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3994739&THISHREF=http://c.moreover.com/click/here.pl%3fz2515233649%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: Form 4 Trubion Pharmaceuticals, For: Jan 29 Filed by: MCKEREGHAN KATHLEENhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3994738&HITNO=4&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3994738&THISHREF=http://c.moreover.com/click/here.pl%3fz2515233509%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3994738&HITNO=4&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3994738&THISHREF=http://c.moreover.com/click/here.pl%3fz2515233509%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: Form 4 Trubion Pharmaceuticals, For: Jan 29 Filed by: Mohler Kendallhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3994737&HITNO=5&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3994737&THISHREF=http://c.moreover.com/click/here.pl%3fz2515233411%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3994737&HITNO=5&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3994737&THISHREF=http://c.moreover.com/click/here.pl%3fz2515233411%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: Form 4 Trubion Pharmaceuticals, For: Jan 29 Filed by: STROMATT SCOTThttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3994736&HITNO=6&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3994736&THISHREF=http://c.moreover.com/click/here.pl%3fz2515233231%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3994736&HITNO=6&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3994736&THISHREF=http://c.moreover.com/click/here.pl%3fz2515233231%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: Trubion Pharmaceuticals, Inc. Announces Initiation of a Phase 2 Study of SBI-087 for the Treatment of Rheumatohttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3919632&HITNO=7&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3919632&THISHREF=http://c.moreover.com/click/here.pl%3fz2473560322%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3919632&HITNO=7&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3919632&THISHREF=http://c.moreover.com/click/here.pl%3fz2473560322%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comKOTA Territory News: Trubion's partner Pfizer initiates Phase II rheumatoid arthritis trialhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3911525&HITNO=8&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3911525&THISHREF=http://c.moreover.com/click/here.pl%3fz2469691836%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3911525&HITNO=8&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3911525&THISHREF=http://c.moreover.com/click/here.pl%3fz2469691836%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comIndividual.com: Trubion's partner Pfizer initiates Phase II rheumatoid arthritis trialhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3913224&HITNO=9&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3913224&THISHREF=http://c.moreover.com/click/here.pl%3fz2470583691%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3913224&HITNO=9&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3913224&THISHREF=http://c.moreover.com/click/here.pl%3fz2470583691%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Trubion says Pfizer starts Phase II study of SBI-087 for rheumatoid arthritishttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3900019&HITNO=10&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3900019&THISHREF=http://c.moreover.com/click/here.pl%3fz2463683621%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3900019&HITNO=10&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3900019&THISHREF=http://c.moreover.com/click/here.pl%3fz2463683621%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Medical News: Trubion Pharmaceuticals, Inc. Announces Initiation Of A Phase 2 Study Of SBI-087 For The Treatment Of Rheumatoid Arthritis (RA)http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3893552&HITNO=11&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3893552&THISHREF=http://c.moreover.com/click/here.pl%3fz2460639093%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3893552&HITNO=11&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3893552&THISHREF=http://c.moreover.com/click/here.pl%3fz2460639093%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBioFind: Trubion Pharmaceuticals, Inc. Announces Initiation Of A Phase 2 Study Of SBI-087 For The Treatment Of Rheumatohttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3893047&HITNO=12&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3893047&THISHREF=http://c.moreover.com/click/here.pl%3fz2460490745%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3893047&HITNO=12&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3893047&THISHREF=http://c.moreover.com/click/here.pl%3fz2460490745%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMedical News Today: Trubion Pharmaceuticals, Inc. Announces Initiation of a Phase 2 Study of SBI-087 for the Treatment of Rheumatoid Arthritis (RA)http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3890771&HITNO=13&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3890771&THISHREF=http://c.moreover.com/click/here.pl%3fz2459366795%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3890771&HITNO=13&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3890771&THISHREF=http://c.moreover.com/click/here.pl%3fz2459366795%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSmartBrief: Trubion Pharmaceuticals, Inc. Announces Initiation of a Phase 2 Study of SBI-087 for the Treatment of Rheumatohttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3890375&HITNO=14&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3890375&THISHREF=http://c.moreover.com/click/here.pl%3fz2459182587%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3890375&HITNO=14&MSIZE=65&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Trubion%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3890375&THISHREF=http://c.moreover.com/click/here.pl%3fz2459182587%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenetic Engineering News: